355 related articles for article (PubMed ID: 17611683)
1. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
Kajiyama H; Shibata K; Terauchi M; Yamashita M; Ino K; Nawa A; Kikkawa F
Int J Oncol; 2007 Aug; 31(2):277-83. PubMed ID: 17611683
[TBL] [Abstract][Full Text] [Related]
2. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.
Yang AD; Fan F; Camp ER; van Buren G; Liu W; Somcio R; Gray MJ; Cheng H; Hoff PM; Ellis LM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4147-53. PubMed ID: 16857785
[TBL] [Abstract][Full Text] [Related]
3. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma.
Dong Y; Tan OL; Loessner D; Stephens C; Walpole C; Boyle GM; Parsons PG; Clements JA
Cancer Res; 2010 Apr; 70(7):2624-33. PubMed ID: 20332224
[TBL] [Abstract][Full Text] [Related]
4. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.
Rosanò L; Spinella F; Di Castro V; Decandia S; Nicotra MR; Natali PG; Bagnato A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1128-31. PubMed ID: 16741062
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
Bagnato A; Rosanò L
Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis.
Lou Y; Preobrazhenska O; auf dem Keller U; Sutcliffe M; Barclay L; McDonald PC; Roskelley C; Overall CM; Dedhar S
Dev Dyn; 2008 Oct; 237(10):2755-68. PubMed ID: 18773493
[TBL] [Abstract][Full Text] [Related]
7. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
[TBL] [Abstract][Full Text] [Related]
8. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
9. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
10. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.
Law KS; Chen HC; Liao SK
Anticancer Res; 2007; 27(2):841-50. PubMed ID: 17465210
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.
Ghoul A; Serova M; Astorgues-Xerri L; Bieche I; Bousquet G; Varna M; Vidaud M; Phillips E; Weill S; Benhadji KA; Lokiec F; Cvitkovic E; Faivre S; Raymond E
Cancer Res; 2009 May; 69(10):4260-9. PubMed ID: 19417139
[TBL] [Abstract][Full Text] [Related]
12. Effects of epithelial-to-mesenchymal transition on acute stress response in human peritoneal mesothelial cells.
Vargha R; Bender TO; Riesenhuber A; Endemann M; Kratochwill K; Aufricht C
Nephrol Dial Transplant; 2008 Nov; 23(11):3494-500. PubMed ID: 18577533
[TBL] [Abstract][Full Text] [Related]
13. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.
Belotti D; Rieppi M; Nicoletti MI; Casazza AM; Fojo T; Taraboletti G; Giavazzi R
Clin Cancer Res; 1996 Oct; 2(10):1725-30. PubMed ID: 9816123
[TBL] [Abstract][Full Text] [Related]
15. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
16. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
Duan Z; Lamendola DE; Duan Y; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
[TBL] [Abstract][Full Text] [Related]
17. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line.
Gao JH; He ZJ; Wang Q; Li X; Li YX; Liu M; Zheng JH; Tang H
Chin Med J (Engl); 2008 Aug; 121(16):1563-8. PubMed ID: 18982869
[TBL] [Abstract][Full Text] [Related]
18. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
19. Low-dose irradiation and short-exposure suboptimal-dose paclitaxel adversely modulate metastatic potential of squamous carcinoma cells.
Lövey J; Fazekas K; Ladányi A; Németh G; Tímár J
Strahlenther Onkol; 2003 Dec; 179(12):812-8. PubMed ID: 14652669
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.
Gorai I; Nakazawa T; Miyagi E; Hirahara F; Nagashima Y; Minaguchi H
Gynecol Oncol; 1995 Apr; 57(1):33-46. PubMed ID: 7535723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
